Overview
Coxib-inhibition of Duodenal Polyp Growth in FAP
Status:
Terminated
Terminated
Trial end date:
2004-04-01
2004-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the development of premalignant adenomatous lesions in the duodenal mucosa of FAP patients.Phase:
Phase 2/Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Oslo University HospitalTreatments:
Rofecoxib
Criteria
Inclusion Criteria:- FAP patient with previous colectomy and confirmed polyposis
Exclusion Criteria:
- Pregnancy
- Malignancy
- NSAID hypersensitivity